Dec 2025
25
Thursday
LyncBio Therapeutics, an Emerging Innovator in ADC Development, Closes Pre-A Financing Round
Dec 25 , 2025
LyncBio Therapeutics (Shanghai) Co., Ltd. ("LyncBio"), a fast-growing biotech company in China dedicated to developing innovative Antibody-Drug Conjugates (ADCs) for both autoimmune disorders and cancer, recently announced the successful completion of the strategic Pre-A financing round.
Nov 2025
21
Thursday
Official Announcement on the Simultaneous Launch of LyncBio Digital Platforms
Nov 21 , 2025
The official website and WeChat Official Account of LyncBio have been officially launched and put into operation simultaneously.